1. Introduction {#sec1}
===============

Central regulation of energy balance in response to feeding cues and environmental factors is regulated by a complex signaling network that integrates multiple brain regions as well as peripheral signals from adipose tissue and the gastrointestinal tract, resulting in physiological responses and altered energy balance specific to nutrient status [@bib1]. Dysregulation of these essential homeostatic mechanisms can lead to obesity and metabolic disorders, including type 2 diabetes [@bib1]. Many of the central circuits that regulate energy balance, specifically those of hypothalamic origin, originate during the first few weeks of life in rodents [@bib2], making this a critical developmental window susceptible to environmental interference. Concurrently, as hypothalamic architecture is developing, white adipose tissues (WAT) depots, which are non-existent at birth, experience rapid expansion [@bib3]. Brown adipose tissue (BAT) depots are also rapidly expanding and responding to environmental changes during this period [@bib4], [@bib5].

The risk of health disorders, including metabolic syndrome, is influenced and exacerbated by negative fetal and neonatal environmental exposures [@bib6], [@bib7]. This phenomenon, referred to as the 'Barker Hypothesis' or the 'developmental origins of adult disease,' intimates that challenges that occur during early development can permanently alter the physiology of the body in adulthood and result in increased susceptibility to disease [@bib8]. In humans, low birth weight is a risk factor for the development of adult obesity and cardiovascular disease [@bib8], [@bib9], [@bib10]. In rodents, intrauterine growth restriction (IUGR) has adverse effects on β-cell mass and the development of insulin resistance and diabetes in adulthood [@bib11], [@bib12], [@bib13].

Physiological glucagon like peptide-1 (GLP-1) signaling acts both peripherally and centrally to stimulate gastric emptying, promote satiety and glucose-induced insulin secretion, and inhibit glucagon release [@bib14]. In adult rodents, central activation of hypothalamic GLP-1 receptor (GLP1R) can transiently repress food intake and weight gain [@bib15], and targeted activation of GLP1R specifically within the ventromedial hypothalamus (VMH) can activate BAT thermogenesis and induce WAT browning [@bib15]. In humans, GLP1R agonists are in clinical use for improving glycemic control in patients with diabetes and have been approved recently for use in weight management [@bib16]. In addition to central expression, GLP1R is widely expressed in other tissues, including in the pancreatic ß-cell, heart, lungs, and kidneys [@bib17], [@bib18]. While these studies support the utility of GLP-1 mimetics in the treatment of health disorders in adults, there is almost no appreciation for their biological action during early postnatal life. We have shown that IUGR in pregnant rats results in low birth weight and the development of obesity and overt diabetes in adult rats [@bib11], [@bib12], [@bib13]. Administration of the GLP1R agonist Exendin-4 (Ex-4) during the neonatal period prevents the development of adult-onset diabetes in IUGR rats and attenuates age related weight gain in both IUGR and sham controls [@bib11], [@bib13].

The role of hormonal signaling during neonatal development in the context of susceptibility to adult disease is not a new concept nor is it restricted to GLP-1. The gut hormone ghrelin, a well characterized appetite stimulator in adult mammals [@bib19], has been shown to play an inhibitory role in hypothalamic circuitry development, with temporal changes in expression during neonatal development having negative metabolic consequences that persist through adulthood [@bib20]. Similarly, manipulation of the adipose-derived hormone leptin, which acts as a signal of stored energy status and an appetite suppressant [@bib19], during the 'leptin surge' of neonatal development [@bib21] alters adult metabolic profiles depending on the timing of manipulation [@bib22]. Recently, maternal high fat diet (HFD) exposure during lactation was shown to impair POMC and AgRP hypothalamic projection development and increase risk of development of hyperinsulinemia, glucose intolerance, and adiposity in the offspring [@bib23]. Together, these findings show that hormones relevant to metabolic regulation in adults can play pivotal roles during neonatal development and, when altered, can permanently change adult health and disease susceptibility.

These studies highlight the biological action of appetite-regulating hormones expressed during the neonatal period and help to identify critical developmental windows susceptible to modulation that could eventually provide a more targeted approach for the treatment and prevention of adult obesity and associated disorders. Here we show that administration of Ex-4 during the first week of life is protective against both age-related and diet-induced obesity. Neonatal Ex-4 leads to browning of parametrial adipose tissue, enhances energy expenditure, and durably alters hypothalamic architecture in female mice. Many of these effects are abrogated by the deletion of GLP1R in the Sim1 expression domain that includes the paraventricular hypothalamic nucleus (PVH), suggesting that this novel role of neonatal GLP1R activation is mediated, in part, through a central mechanism involving the PVH.

2. Materials and methods {#sec2}
========================

2.1. Animal studies {#sec2.1}
-------------------

### 2.1.1. Breeding and housing {#sec2.1.1}

All animal experiments were performed according to procedures approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania. Mice were housed under standard conditions (average 22 °C) and allowed free access to food and water. Animals spontaneously delivered, and, at birth, the litters were randomly culled or fostered to eight. Animals were weaned at 21 days of age then allowed free access to either chow diet, 10% LFD, or 45% HFD (Research Diets, New Brunswick, NJ) and maintained with 12-hour light and dark cycles.

### 2.1.2. Ex-4 preparation {#sec2.1.2}

Ex-4 was prepared as a 1 μmol/l stock in 0.9% sodium chloride, and stored at −80 °C in single use aliquots. Just before injection, aliquots were thawed and diluted in 1% BSA 0.9% sodium chloride.

### 2.1.3. Experimental conditions {#sec2.1.3}

Experiments involving neonatal Ex-4 (Bachem \[H-8730\] King of Prussia) administration were performed using wild type C57BL/6N mice (Charles River) or mice with the conditional loss of *Glp1r* [@bib24] generated by breeding *Glp1r* floxed mice with Sim1Cre deleter strain mice, obtained from B. Kublaoui (Children\'s Hospital of Philadelphia) [@bib25], resulting in littermate control *Glp1r*^loxP/loxP^ and experimental Sim1Cre;*Glp1r*^loxP/loxP^ mice. Injections were as follows: Vehicle treated (1% BSA in 0.9% saline) and Ex-4 treated (1 nmol/kg initial body weight). Vehicle or Ex-4 was injected subcutaneously daily for 6 days, beginning 16--20 h after birth. Animal weights were monitored regularly.

### 2.1.4. Body composition {#sec2.1.4}

Body composition was determined by NMR (Echo Medical Systems, Houston, TX), as described previously [@bib26].

### 2.1.5. Indirect calorimetry {#sec2.1.5}

For indirect calorimetry measurements, animals were individually housed for 72 h. Raw values were normalized to lean mass and data represent values over a 24 h period. Energy expenditure was measured as previously described [@bib27] and calculated according to the following formula. Total energy expenditure (heat) = Calorific value (CV) × VO~2~, where CV = 3.815 + 1.232 × RER.

### 2.1.6. Intraperitoneal glucose tolerance {#sec2.1.6}

For glucose tolerance tests, 28 day old female and male mice were fasted overnight and given 1 g/kg glucose via intra-peritoneal (IP) injection; blood glucose was measured by handheld glucometer at 0, 15, 30, 60, and 120 min after injection.

### 2.1.7. Core body temperature {#sec2.1.7}

Mice were anesthetized with isofluorane and implanted with subcutaneous transponder devices longitudinally parallel but to one side of the spine (Animal Identification Transponder IPTT-300, Bio Medic Data Systems \[BMDS\]) below the intrascapular region. Mice were allowed to recover for 7 days prior to starting data collection of core body temperature using a compatible BMDS Smart Probe scanning device. Temperature data were collected for 5 days at the end of the dark cycle (6 am) and the end of the light cycle (6 pm).

2.2. Histology {#sec2.2}
--------------

Antisera were as follows: UCP1 (ab10983, Abcam, Cambridge, UK), TH (AB3036) and NPY (AB1583) (Millipore, Temecula, CA), AgRP (H-003-57), and POMC (H-029-30) (Phoenix Pharmaceuticals, INC, Burlingame, CA). Brains were fixed for 24 h at 4 °C in 4% paraformaldehyde (PFA), cryoprotected in 30% sucrose for 24 h, embedded and frozen on dry ice, and stored at −80 °C. 14 μm thick serial coronal cryosections were cut and mounted on glass slides prior to staining. For *in situ* analysis of *Glp1r* expression (ACD RNAscope^®^, Newark, CA), brains were dissected onto dry ice and stored at −80 °C until processing using the manufacturer\'s protocol (Probe-Mm-Glp1r-E7-E13, RNAscope^®^ 2.0 HD Reagent Kit). Fat pads were dissected and fixed in 4% PFA overnight at 4 °C. Paraffin embedded sections were incubated with anti-UCP1 (1:1000) antibody followed by detection using the ABC Vectastain-Elite kit (Vector Laboratories, INC., Burlingame, CA) or for immunofluorescence UCP1 (1:500) and TH (1:500).

2.3. Quantitative RT-PCR (QPCR) {#sec2.3}
-------------------------------

For isolation of total RNA from frozen adipose tissue, samples were homogenized in Trizol (Invitrogen) and processed (Maxwell, Promega). RNA was reverse-transcribed to cDNA with Super Script II (Invitrogen). QPCR was performed on a Bio-Rad CFX384. Primer sequences can be found in [Table S1](#appsec3){ref-type="fn"}.

2.4. Ex vivo oxygen consumption {#sec2.4}
-------------------------------

Six 5 mg portions of each parametrial fat pad were dissected from female mice. Three pieces were incubated in vehicle (n = 3), and three pieces were incubated in 10 uM isoproterenol for 1 h in DMEM-F12 containing fetal bovine serum prior to analysis using a Clark-type electrode as previously described with the following minor modifications [@bib28]. The superfusion medium was maintained at 30 °C using a water bath. The composition of the perfusion solution was 114 mM NaCl, 5 mM KCl, 1 mM MgCl~2~, 1 mM NAHPO~4~, 2.2 mM CaCl~2~, 10 mM HEPES, 5 mM glucose (pH 7.4).

2.5. Statistics {#sec2.5}
---------------

All data are represented as mean +/− SEM. Statistical significance was assessed by two-tailed Student\'s t-test, unpaired heteroscedastic t-test, One-way or Two-way ANOVA as indicated in figure legends. Differences were considered significant if p \< 0.05.

3. Results {#sec3}
==========

3.1. Decreased adiposity and increased energy expenditure in adult mice treated with Ex-4 during the neonatal period {#sec3.1}
--------------------------------------------------------------------------------------------------------------------

To determine the effect of neonatal Ex-4 administration on adult adiposity and metabolism, C57BL/6N mice were injected with 1 nmol/kg Ex-4 between 16 and 20 h after birth and then daily for a total of 6 consecutive days. By postnatal day 28 (P28), Ex-4 attenuated weight gain in males by 14.6% ([Figure 1](#fig1){ref-type="fig"}A) and reduced both inguinal and epididymal fat pad weights by 21% and 32%, respectively ([Figure 1](#fig1){ref-type="fig"}B). The apparent reductions in male adiposity were confirmed by nuclear magnetic resonance (NMR) spectroscopy ([Figure 1](#fig1){ref-type="fig"}C) and were consistent with a trend toward reduced leptin serum levels ([Figure 1](#fig1){ref-type="fig"}D). Neonatal Ex-4 did not have an effect on weight gain in female mice ([Figure 1](#fig1){ref-type="fig"}E) but did significantly reduce parametrial fat pad weight by P28 ([Figure 1](#fig1){ref-type="fig"}F). There was no difference in body composition in female mice by NMR ([Figure 1](#fig1){ref-type="fig"}G); however, there was a significant reduction in serum leptin ([Figure 1](#fig1){ref-type="fig"}H). To determine whether the observed fat loss had negative metabolic consequences [@bib29], we assessed glucose homeostasis ([Figure S1A--D](#appsec3){ref-type="fn"}). Nonfasting blood glucose was transiently reduced in both females and males at P13 but indistinguishable from vehicle treated mice by P28 ([Figure S1A and B](#appsec3){ref-type="fn"}). Ex-4 had no effect on glucose tolerance in females or males at P28 ([Figure S1C--D](#appsec3){ref-type="fn"}). A survey of additional serum markers revealed no significant effect of neonatal Ex-4 treatment on nonesterified free fatty acids, triglycerides, or adiponectin in either gender at this age ([Figure S1E--G](#appsec3){ref-type="fn"}). Serum resistin was reduced by 25% in females and unaffected in males ([Figure S1H](#appsec3){ref-type="fn"}). Serum insulin at P28 was also reduced by 58% in males treated with neonatal Ex-4 ([Figure S1I](#appsec3){ref-type="fn"}).Figure 1**Neonatal Ex-4 decreases adiposity in male and female mice**. (A--H) Analysis of C57BL/6N male (A--D) and female (E--H) mice given daily injections of vehicle (saline) or Ex-4 (1 nmol/kg birth weight). Mean body weight of male (A) and female (E) mice at postnatal days 1, 17, and 28. n = 4--9 mice per gender and treatment group. P28 fat pad weights from male (B) and female (F) mice normalized to body weight. n = 4--9 mice per gender and treatment group. NMR analysis of 25 day old male (C) and female (G) mice. n = 6--9 mice/group. Plasma leptin measured in P28 male (D) and female (H) mice. n = 4--9 mice per gender and treatment group. All data are expressed as mean ± SEM; \*, p \< 0.05, relative to corresponding vehicle (Two-tailed Student\'s t test).Figure 1

Despite the reduction in male body weight, we observed no differences in VO~2~ or energy expenditure at 8--10 weeks of age ([Figure 2](#fig2){ref-type="fig"}A--C). By contrast, neonatal administration of Ex-4 to female mice resulted in increased VO~2~ and energy expenditure during both light and dark cycles ([Figure 2](#fig2){ref-type="fig"}D--F). While body weight was significantly reduced in both genders at this age ([Figure 2](#fig2){ref-type="fig"}G), fat mass was no longer reduced in Ex-4 treated male mice, suggesting a more transient effect of Ex-4, whereas Ex-4 treated female mice began to display a trend in lower fat mass ([Figure 2](#fig2){ref-type="fig"}H). Cumulatively, these data suggest that activation of GLP1R during early development is protective against weight gain and adiposity and increases energy expenditure in a gender-specific manner.Figure 2**Neonatal Ex-4 enhances energy expenditure and protects against weight gain in adulthood**. (A--F) Indirect calorimetry assessed in 8--10 week old male (A--C) and female (D--F) mice. Oxygen consumption for male (A--B) and female (D--E) mice normalized to lean mass. Energy expenditure for male (C) and female (F) mice calculated and normalized to lean mass. n = 4--5 mice/group. (G) Body weight of 8--10 week old male and female mice. n = 5 mice/group. (H) NMR analysis of 8--10 week old male and female mice. n = 5 mice/group. (A--F) \*, p \< 0.05, relative to corresponding vehicle (Two-way ANOVA with Bonferonni Posthoc test). (G--H). \*, p \< 0.05, relative to corresponding vehicle (Two-tailed Student\'s t test).Figure 2

3.2. Neonatal Ex-4 protects adult female mice from diet-induced obesity through enhanced energy expenditure {#sec3.2}
-----------------------------------------------------------------------------------------------------------

HFD can exacerbate the phenotype resulting from alterations in fetal and neonatal environments [@bib30]. To assess the long-term protective effect of neonatal Ex-4 on body weight regulation, mice treated with neonatal Ex-4 or vehicle were weaned onto a 10% low fat diet (LFD) or 45% HFD for 42 weeks. In LFD-fed males, Ex-4 attenuated weight gain for the first 24 weeks ([Figure 3](#fig3){ref-type="fig"}A), associated with reduced fat mass by NMR assessed at postnatal week 9 ([Figure S2A](#appsec3){ref-type="fn"}); however, there was no difference in weight in HFD-fed males, and weight was not different on either diet after 25 weeks. Neonatal Ex-4 treated LFD-fed females achieved a modest reduction in weight gain by postnatal week 9 ([Figure 3](#fig3){ref-type="fig"}B), which corresponded with a significant reduction in fat mass by NMR ([Figure S2B](#appsec3){ref-type="fn"}). In striking contrast to males, however, neonatal Ex-4 protected adult females from diet-induced obesity, an effect that persisted through 42 weeks ([Figure 3](#fig3){ref-type="fig"}B). This was accompanied by a reduction in parametrial fat pad weight after HFD ([Figure 3](#fig3){ref-type="fig"}D) and a reduction in total fat mass by NMR ([Figure 3](#fig3){ref-type="fig"}E). We observed no apparent change in inguinal depots ([Figure 3](#fig3){ref-type="fig"}D). Despite altered body weight, treatment had no impact on food or fluid intake in female mice ([Figure S2C--D](#appsec3){ref-type="fn"}).Figure 3**Neonatal Ex-4 protects adult female mice from diet-induced obesity through enhanced energy expenditure**. (A--E) After neonatal vehicle or Ex-4 administration, mice were weaned onto a 10% LFD or 45% HFD. Body weight of male (A) and female (B) mice monitored for 42 weeks. Data expressed as mean ± SEM; n = 10--15 mice/group. \*, p \< 0.05, relative to corresponding vehicle. (C--E) Mice sacrificed at postnatal week 42 for dissection of male (C) and female (D) inguinal and perigonadal fat depots. Tissue weights normalized to body weight and data represented as means ± SEM; n = 3--9 mice/group. \*, p \< 0.05 relative to vehicle LFD, ^\#^, p \< 0.05 relative to vehicle HFD. (E) NMR analysis of 42 week old females. Values represented as means ± SEM; n = 4 mice/group. \*, p \< 0.05 relative to vehicle LFD, ^\#^, p \< 0.05 relative to vehicle HFD (Two-tailed Student\'s t test). (F--H) Indirect calorimetry performed on 42 week old female mice. Oxygen consumption (F--G) shown over 24 h period (F) or as a 24 h average (G). Energy expenditure shown as a 24 h average. All raw values normalized to lean mass. Data expressed as mean ± SEM; n = 4--8 mice/group. \*, p \< 0.05, relative to corresponding vehicle LFD, ^\#^, p \< 0.05 relative to vehicle HFD. (Two-way ANOVA with Tukey Posthoc test).Figure 3

Strikingly, in HFD-fed female mice, Ex-4 was able to reverse the negative effect of HFD on oxygen consumption ([Figure 3](#fig3){ref-type="fig"}F,G), carbon dioxide output ([Figure S3A and B](#appsec3){ref-type="fn"}), and energy expenditure ([Figure 3](#fig3){ref-type="fig"}H), restoring these metabolic measures to levels similar to those of LFD-fed mice. Both LFD- and HFD-fed Ex-4 treated females displayed a lower respiratory exchange ratio (RER), suggesting that fat is more readily available for oxidation ([Figure S3C and D](#appsec3){ref-type="fn"}). Altogether, these findings indicate that neonatal Ex-4 can protect against the deleterious effects of HFD on body weight, adiposity, and energy expenditure in adult animals in a gender specific manner.

3.3. Neonatal Ex-4 promotes browning of female perigonadal WAT {#sec3.3}
--------------------------------------------------------------

The persistent effect of short-term neonatal Ex-4 administration on body weight and adiposity during a critical window of white adipose tissue development prompted a histological analysis of the WAT. In P28 male mice, the thermogenic protein UCP1 was undetectable in epididymal fat pads ([Figure 4](#fig4){ref-type="fig"}A--D). By contrast, in P28 females, neonatal Ex-4 enhanced the appearance of UCP1 positive multilocular cells in the parametrial fat pad ([Figure 4](#fig4){ref-type="fig"}E--H). In both genders, analysis of inguinal depots revealed an abundance of multilocular cells with similar UCP1 levels and distribution regardless of treatment at P28 ([Figure S4A](#appsec3){ref-type="fn"}). Together, these observations highlight an architectural change specific to adult female parametrial adipose morphology, resulting in increased beige adipocytes after neonatal Ex-4 administration.Figure 4**Neonatal Ex-4 promotes browning of female perigondal WAT**. Histological analysis of perigonadal adipose tissue from P28 male (A--D) and female (E--H) mice stained with anti-UCP1 (n = 4). Images captured at 4× (A, B, E, F) and 40× (C, D, G, H) magnification. (I--L) Parametrial fat pads dissected from 42 week old females and immunostained with anti-UCP1: LFD 40X (I--J) or HFD 60X (K--L) magnification; n = 6--10 mice/group. RT-qPCR of perigonadal fat pads isolated from P28 female (M) and male (N) mice treated with neonatal Ex-4 or Vehicle. Values are means ± SEM for 4--9 mice per gender and treatment group. \*, p \< 0.05, relative to corresponding vehicle (Unpaired heteroscedastic t test). ND, transcript not detectable. (O) RT-qPCR of parametrial fat from female mice at 42 weeks. Data expressed as means ± SEM, n = 10--15 mice/group. \*, p \< 0.05, relative to vehicle LFD, ^\#^, p \< 0.05 relative to vehicle HFD, Unpaired heteroscedastic t test). (P) Parametrial adipose isolated from P28 females. Explants were treated with vehicle or 10 μM ISO *in vitro* for 1 h prior to measurement of oxygen consumption with a Clark-type electrode (n = 4). Values expressed as means ± SEM; n = 4 mice/group. \*, p \< 0.05, relative to neonatal Ex-4- and ISO-, ^\#^, p \< 0.05 relative to Neonatal Ex-4 -- and ISO + (Two-tailed Student\'s t test). (Q) Core body temperature monitored twice daily for 5 days. Values expressed as means ± SEM; n = 5 mice/treatment. \*, p \< 0.05 (Two-way ANOVA).Figure 4

To assess the durability of neonatal Ex-4 in the context of a HFD, we analyzed fat depots after LFD or HFD feeding ([Figure 4](#fig4){ref-type="fig"}I--L). The enhanced browning effect of parametrial fat pads was maintained at 42 weeks of age in LFD-fed female mice ([Figure 4](#fig4){ref-type="fig"}I vs J). Though to a lesser degree, multilocular UCP1 expressing cells were also present in the parametrial fat pads of neonatal Ex-4 treated HFD-fed females ([Figure 4](#fig4){ref-type="fig"}L). We observed similar distribution and expression of UCP1 in inguinal depots at both P28 and at 42 weeks on a LFD ([Figure S4A and B](#appsec3){ref-type="fn"}). However, HFD induced a loss of UCP1 expression in the inguinal fat pads at 42 weeks; this was partially preserved by neonatal exposure to Ex-4 ([Figure S4B](#appsec3){ref-type="fn"}).

Consistent with adipose morphology, we observed enhanced expression of the brown fat genes *Cox8b* and *CideA* with trending increases in both *Ucp1* and *Cox7a1* in P28 neonatal Ex-4 treated female mice ([Figure 4](#fig4){ref-type="fig"}M). Similarly, at 42 weeks, neonatal Ex4 elevated *Ucp1*, *Pgc1a*, and *Prdm16* transcript in parametrial fat from LFD-fed females ([Figure 4](#fig4){ref-type="fig"}O). In males however, no changes in the expression of brown fat marker genes in epididymal pads were observed at P28 or at 42 weeks ([Figure 4](#fig4){ref-type="fig"}N, [S4C](#appsec2){ref-type="sec"}). Gene expression analysis of inguinal depots isolated from both genders also revealed no effect of neonatal Ex-4 on brown fat marker genes (data not shown).

In contrast to the increased expression of genes associated with thermogenesis in females, neonatal Ex-4 was associated with a downward trend in expression of genes involved in adipogenesis and lipid synthesis, an effect that was enhanced under HFD-fed conditions ([Figure S5A](#appsec3){ref-type="fn"}). mRNA levels of *Pparγ2*, *C/ebpα*, *Srebp1c*, *HSL*, *Dgat1*, *and Leptin* were decreased in HFD-fed Ex-4 mice as compared with HFD-fed vehicle controls, whereas expression of *Fas* was reduced by HFD alone and not further altered by neonatal Ex4 ([Figure S5A](#appsec3){ref-type="fn"}). Expression of these genes in male epidydimal fat pads was affected by diet but not specifically by neonatal Ex4 ([Figure S5B](#appsec3){ref-type="fn"}). Additionally, no difference was detected in the expression of brown fat markers or adipogenic/lipogenic/lipolytic factors in the inguinal fat pads regardless of diet or gender (data not shown). These data indicate that neonatal Ex-4 promotes the brown fat gene program specifically in female parametrial WAT.

To determine whether the appearance of UCP1 in parametrial pads of neonatal Ex-4 treated mice translated into a functional consequence on the thermogenic capacity of this WAT depot, we measured oxygen consumption of parametrial explants from neonatal vehicle or Ex-4 treated female P28 mice ([Figure 4](#fig4){ref-type="fig"}P). Neonatal Ex-4 did not influence basal oxygen consumption but did enhance isoproterenol (ISO)-stimulated oxygen consumption by 47% ([Figure 4](#fig4){ref-type="fig"}P). Together, these data revealed an enhanced appearance of UCP1 positive cells in the parametrial depot of neonatal Ex-4 treated mice that is associated with a functional increase in uncoupled respiration after beta-agonist stimulation. Further, an assessment of core body temperature to determine whether neonatal Ex-4 affects adaptive thermogenesis revealed a significant increase in core body temperature in Ex-4 treated female mice ([Figure 4](#fig4){ref-type="fig"}Q) at 8--10 weeks of age that corresponded with the increased oxygen consumption and energy expenditure ([Figure 2](#fig2){ref-type="fig"}D--F). In contrast, neonatal Ex-4 treatment did not raise the core body temperature of male mice ([Figure S6](#appsec3){ref-type="fn"}). Altogether, these changes in core body temperature in concert with increased oxygen consumption and carbon dioxide output prior to changes in body weight suggest that thermogenic changes could contribute to weight loss and to the persistent elevation in energy expenditure during adulthood. These findings suggest that an acute intervention with Ex-4 during the neonatal period in female mice increases browning potential in parametrial fat depots and highlights a critical neonatal window during which adipose tissue may be susceptible to re-programming.

3.4. Neonatal Ex-4 durably alters NPY projections to the PVH {#sec3.4}
------------------------------------------------------------

Neonatal Ex-4 treatment is protective against weight gain and adiposity during adulthood, in part through enhanced energy expenditure and browning of parametrial WAT. The PVH acts as a coordinating center for endocrine, autonomic, and behavioral signals [@bib25], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36]. The response to these signals is integrated in the PVH and ultimately regulates energy balance [@bib33], [@bib35]. Additionally, sympathetic input to BAT and WAT depots, which contribute to the regulation of energy homeostasis, originates in the PVH [@bib35], [@bib36]. Therefore, we evaluated NPY projections to the PVH to determine whether neonatal Ex-4 affected these adult neuronal projections. We found a robust reduction in NPY-positive projections to the PVH at 4 weeks of age in neonatal Ex-4 treated female mice that persisted to at least 42 weeks ([Figure 5](#fig5){ref-type="fig"}). In line with a previous report [@bib37], vehicle treated HFD-fed mice displayed a significant reduction in NPY neuronal projections when compared to LFD-fed controls ([Figure S7](#appsec3){ref-type="fn"}). Wei et al. report that HFD exposure results in a physical loss of projections originating in the arcuate nucleus of the hypothalamus (ARH) that target the PVH [@bib37]. Interestingly, our findings show that neonatal Ex-4 was able to reverse the HFD-induced decrease in NPY fiber density in the PVH ([Figure S7](#appsec3){ref-type="fn"}), possibly indicating a restoration of projections to the PVH.Figure 5**Neonatal Ex-4 durably reduces NPY fiber density in the PVH**. Histological analysis of NPY-IR in the PVH at 4, 8--10, and 42 weeks in neonatal vehicle or Ex-4 treated female mice. Images representative of n = 3--4. Mice weaned at P21 on to standard chow (4 and 8--10 weeks) or LFD (42 weeks). Scale Bar 150 μm.Figure 5

3.5. Sim1Cre deletion of Glp1r attenuates the impact of neonatal Ex-4 on adult body weight and WAT browning {#sec3.5}
-----------------------------------------------------------------------------------------------------------

Given the importance of the PVH in the regulation of energy balance and our observations of persistently altered NPY projections in the PVH after neonatal Ex-4 ([Figure 5](#fig5){ref-type="fig"}), we postulated a role for early PVH specific GLP1R signaling in mediating the protective effects of Ex-4. GLP1R is expressed throughout the hypothalamus ([Figure 6](#fig6){ref-type="fig"} A, C, E, G) and is particularly abundant within the PVH ([Figure 6](#fig6){ref-type="fig"}A, A′). By crossing *Glp1r* floxed mice with the Sim1Cre deleter strain that specifically targets the PVH, supraoptic nucleus (SON) within the hypothalamus, as well as parts of the amygdala, we were able to conditionally and efficiently delete *Glp1r* from the Sim1 expression domain ([Figure 6](#fig6){ref-type="fig"}B, B′, D, D′) with no effect on expression in other hypothalamic regions ([Figure 6](#fig6){ref-type="fig"}F, H). Similar to our initial findings, neonatal Ex-4 treated 8 week old *Glp1r*^loxP/loxP^ (control) female mice weighed 9% less than vehicle treated control mice ([Figure S8A](#appsec3){ref-type="fn"}). However, when *Glp1r* was deleted from the Sim1 expression domain (Sim1Cre;*Glp1r*^*l*oxP/loxP^), neonatal Ex-4 treatment had no effect on body weight ([Figure S8A](#appsec3){ref-type="fn"}). Similarly, neonatal Ex-4 treatment resulted in a 32% reduction in parametrial fat pad weight in Ex-4 treated *Glp1r*^loxP/loxP^ mice. Protection from weight gain ([Figure S8A](#appsec3){ref-type="fn"}) and adiposity ([Figure S8B](#appsec3){ref-type="fn"}) were attenuated in Ex-4 treated Sim1Cre;*Glp1r*^*l*oxP/loxP^ female mice ([Figure S8](#appsec3){ref-type="fn"}).Figure 6**Sim1Cre deletion of *Glp1r* attenuates impact of neonatal Ex-4 on adult body weight and WAT browning.***Glp1r* expression in the hypothalamus in P28 female mice by *in situ* in *Glp1r*^loxP/loxP^ (control) and Sim1Cre;*Glp1r*^loxP/loxP^ mice (A--H). PVH: paraventricular nucleus of the hypothalamus, SON: supraoptic nucleus, DMH: dorsal medial hypothalamus, ARH: arcuate nucleus of the hypothalamus. (Scale Bar 150 μm PVH and ARH, 100 μm SON and DMH). (I--O) Histological analysis of parametrial adipose tissue. Parametrial fat pads from P28 *Glp1r*^loxP/loxP^ (control) and Sim1Cre;*Glp1r*^loxP/loxP^ female mice stained with anti-UCP1 and anti-TH (I--M UCP1/TH merge Scale Bar: 10 μm, I′--M′ UCP1, I″--M″ TH, I‴-M‴ merge Scale Bar 2.5 μm). IR of UCP1 and TH in parametrial WAT quantified using ImageJ (N--O). Values are means ± SEM, n = 3--5 mice/group. \*p \< 0.05 relative to Veh *Glp1r*^loxP/loxP^ (Two-tailed Student\'s t test).Figure 6

Neonatal Ex-4 treatment durably altered parametrial fat pads resulting in the browning of this fat pad in adult female mice ([Figure 4](#fig4){ref-type="fig"}F,H, J, L). In order to determine whether central neonatal GLP1R signaling contributes to WAT browning, we assessed the parametrial fats pads of female *Glp1r*^loxP/loxP^ and Sim1Cre;*Glp1r*^*l*oxP/loxP^ mice. We observed enhanced multilocular UCP1 positive adipocytes that also stained positively for tyrosine hydroxylase (TH), a marker for noradrenergic parenchymal fibers [@bib40] ([Figure 6](#fig6){ref-type="fig"}J, N, O). The appearance of multilocular UCP1 positive adipocytes was region specific ([Figure 6](#fig6){ref-type="fig"}J) while other parts of the parametrial fat pad maintained a more normal WAT morphology, similar to vehicle treated counterparts ([Figure 6](#fig6){ref-type="fig"}I, K). Despite neonatal exposure to Ex-4, Sim1Cre;*Glp1r*^*l*oxP/loxP^ mice displayed UCP1 and TH levels comparable to vehicle treated *Glp1r*^loxP/loxP^ mice ([Figure 6](#fig6){ref-type="fig"}M, N, O). Interestingly, UCP1 expression in vehicle treated Sim1Cre;*Glp1r*^loxP/loxP^ mice was significantly reduced compared to vehicle treated *Glp1r*^loxP/loxP^ mice ([Figure 6](#fig6){ref-type="fig"}L, N), suggesting an endogenous role of central GLP1R signaling in the development and/or maintenance of resident beige adipocytes in the parametrial fat pads of female mice. Altogether, these findings support a role for neonatal GLP1R signaling in the Sim1 expression domain in Ex-4 mediated protection from weight gain, adiposity, and browning of parametrial fat pads.

3.6. Neonatal Ex-4 effect on NPY and POMC fiber density in the PVH requires intact GLP1R signaling in the Sim1 expression domain {#sec3.6}
--------------------------------------------------------------------------------------------------------------------------------

Neonatal Ex-4 treatment is protective against weight gain and adiposity during adulthood, in part through enhanced energy expenditure and browning of parametrial WAT. The central regulation of these processes [@bib1], [@bib25], [@bib36], [@bib38], [@bib40], [@bib41], [@bib42] prompted the evaluation of orexigenic and anorexigenic factors that are responsible for regulating energy expenditure and for the response to appetite triggering and suppressive signals. We observed a dramatic ∼65% reduction of NPY and AgRP fiber densities in the PVH of 4-week old neonatal Ex-4 *Glp1r*^loxP/loxP^ mice ([Figure 7](#fig7){ref-type="fig"}A--F, Q) with a corresponding increase in POMC fiber density ([Figure 7](#fig7){ref-type="fig"}M--N, Q). This effect was abrogated by deletion of *Glp1r* from the Sim1 expression domain ([Figure 7](#fig7){ref-type="fig"}J--L, P, Q). We considered the possibility that Ex-4 mediated alterations in fiber densities result from changes in the content of these neurohormones in the ARH; however, no differences in ARH content were observed ([Figure 7](#fig7){ref-type="fig"}R). As in females, neonatal Ex-4 treatment in male mice markedly reduced NPY fiber density in the PVH ([Figure S9A, C](#appsec3){ref-type="fn"}). Further, the deletion of *Glp1r* from the Sim1 expression domain reversed the effect of neonatal Ex-4 treatment in 4 week old male mice ([Figure S9B](#appsec3){ref-type="fn"}, D). These findings could suggest a sexual dimorphic difference downstream of the PVH or working directly at the level of WAT. These findings also leave open the possibility of additional areas, both central and peripheral, that could be contributing to the gender differences observed with neonatal Ex-4 exposure. Cumulatively, these findings demonstrate that neonatal Ex-4 offers protection from weight gain and adiposity through browning of fat depots and altered hypothalamic projection patterning. The data further suggest that Ex-4 mediated browning of parametrial adipose tissue and alterations in hypothalamic architecture both require intact GLP1R signaling within the Sim1 expression domain.Figure 7**Neonatal Ex-4 effect on NPY and POMC fiber density in the PVH is reversed by Sim1Cre *Glp1r* deletion.** Histological analysis of orexigenic neuropeptides NPY (A, D, G, J) and AgRP (B, E, H, K) and the anorexigenic neuropeptide POMC (M−P) evaluated in the hypothalamus of 4 week old *Glp1r*^loxP/loxP^ (control) and Sim1Cre;*Glp1r*^loxP/loxP^ female mice. IR of NPY, AgRP and POMC quantified using ImageJ (Q--R). Values are means ± SEM n = 4--6 mice/group. Scale Bar 150 μm. \*, p \< 0.05, \*\*, p \< 0.01 relative to Veh *Glp1r*^loxP/loxP^ by (Two-way ANOVA with Tukey Posthoc test).Figure 7

4. Discussion {#sec4}
=============

Alterations to fetal and neonatal environments can result in adult predisposition to obesity, metabolic syndrome, and diabetes. The concept that the neonatal environment can influence hypothalamic projection development was recently suggested by the elegant observation that modification of maternal diet during gestation and lactation can alter hypothalamic axonal development and adult body weight regulation [@bib23]. Here, we define a discrete neonatal window and a specific signaling pathway, the manipulation of which has a long-term impact on body weight regulation. Short-term treatment of neonatal mice with a GLP1R agonist, Ex-4, durably alters hypothalamic architecture and results in resistance to diet-induced weight gain and adiposity through a permanent browning of parametrial WAT depots and increased energy dissipation in adult female mice. The period of Ex-4 administration represents an important window for the development of hypothalamic circuitry relevant to the regulation of energy expenditure and feeding behavior as well as for the development of WAT. A permanent remodeling of hypothalamic circuitry is observed in mice after neonatal Ex-4 exposure through 42 weeks of age. Within the PVH, the diminished NPY and AgRP fiber density and the antagonistic increase in POMC fiber density was lost with the genetic disruption of GLP1R signaling in the Sim1 expression domain. These findings implicate the GLP1R signaling pathway as a target for developmental intervention to prevent adult obesity.

Our observations suggest that neonatal Ex-4 affects multiple components contributing to daily energy expenditure, including basal metabolic rate, diet-induced thermogenesis, and physical activity [@bib43]. Ex-4 enhanced respiration as well as other metabolic parameters during both light and dark cycles. During the dark (active) cycle, Ex-4 enhanced locomotor activity (data not shown), which may, in part, explain increases in energy expenditure during this phase; however, energy expenditure was also elevated during the light (resting) phase when energy dissipation occurs through alterations in basal metabolic rate. We postulate that neonatal Ex-4 modulates basal metabolic rate by enhancing the thermogenic capacity of parametrial WAT. This is supported by the appearance of multilocular adipocytes exhibiting enhanced expression of UCP1, an essential component of the high mitochondrial content of BAT and beige fat. Gene expression analyses coincided with these observations, with increases in multiple brown fat marker genes in parametrial fat pads from Ex-4 treated female mice at P28. These observations were consistent with morphological changes found in 42-week old parametrial fat pads, in which UCP1 positive adipocytes were observed, regardless of diet. Further supporting fundamental alterations in metabolic rate, we observed a higher capacity for oxygen consumption after β-adrenergic stimulation of parametrial adipose explants dissected from neonatal Ex-4 treated female mice, illustrating functional changes in this fat depot.

We observe a gender selective effect of neonatal administration of Ex-4, which could relate to previously described sexual dimorphisms. Development, expansion, and metabolic function of adipose are influenced by sex hormones [@bib44], [@bib45] and X chromosome dosage [@bib46]. The origin and distribution of depot-specific progenitors and preadipocytes vary by gender and affects the capacity for growth, proliferation, and differentiation [@bib47], [@bib48]. Female rodents have a higher temperature threshold for thermogenic response [@bib49] and are thus more sensitive to ambient colony temperature than males. Additionally, female rodents are more susceptible to persistent metabolic disturbances in response to alterations in maternal diet during fetal and neonatal development [@bib50], [@bib51]. In these reports, and consistent with our findings, while males were similarly affected by changes in maternal diet, male rodents were resistant to permanent or long-term effects [@bib50], [@bib51]. Interestingly, many of these observations translate to humans. Per kg of tissue, WAT depots in women are more metabolically active than complementary depots in men and exhibit higher expression of genes involved in thermogenesis and mitochondrial function, including Ucp1 [@bib52]. With these points in mind, it is possible that alternative conditions will be required to reveal the role of neonatal GLP1R signaling in adult metabolism in males.

Many regions within and outside of the hypothalamus are necessary for the regulation of energy balance; however, the PVH is particularly relevant as a pivotal integration point in the central regulation of energy homeostasis, in addition to acting as a major source of sympathetic input to both WAT and BAT [@bib36], [@bib38], [@bib40], [@bib41], [@bib53]. We postulate that Ex-4 permanently alters the projections that are established during a critical developmental window. We observed a 65% reduction in NPY and AgRP fibers within the PVH of neonatal Ex-4 treated mice, which coincided with a modest but significant increase in POMC fibers. Conditional Cre-mediated deletion of *Glp1r* from the Sim1 expression domain, which contains the PVH, abrogates Ex-4 mediated alterations of both POMC and NPY projections to the PVH. ARH populations of NPY and POMC neurons begin to form during fetal development [@bib54]; however, circuitry connecting these defining regions of the hypothalamus does not begin to form until the early neonatal period in rodents [@bib2]. Genetic ablation of *Glp1r* abrogated Ex-4 mediated alterations in fiber densities within the PVH; however, ARH content of NPY, POMC, and AgRP was unaffected by either Ex-4 treatment or the loss of *Glp1r*.

The strong evidence supporting a role for the PVH in regulating energy expenditure [@bib25], [@bib36], [@bib42], [@bib55], sympathetic outflow [@bib36], [@bib38], [@bib40], as well as our observations of abrogated Ex-4 effect with the loss of GLP1R in the PVH suggests that the PVH is a likely target of neonatal Ex-4. It is, however, important to note that the Sim1 expression domain directing Cre recombinase expression includes neuronal populations located within the supraoptic nucleus and the amygdala [@bib25], [@bib56], both of which express *Glp1r*. *Glp1r* is expressed in other central regions that could also contribute to these observations, including the hindbrain, known for its involvement in the regulation of energy balance and for endogenous GLP-1 production, as well as in the ventral tegmental area, nucleus accumbens, and lateral parabrachial nucleus [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62]. Interestingly, we did not observe altered food intake in adult mice after Ex-4 treatment, which could suggest that our treatment window is specific to the establishment of networks regulating energy expenditure. Circuitry regulating feeding behavior may develop later and fall outside our treatment window, which may suggest specific and distinct periods available for intervention.

The incidence of obesity and its related disorders is affecting humans at an alarming rate. Even modest reductions in body weight, as low as 5% of initial weight, have been shown to improve blood pressure, lipid profile, insulin sensitivity, and glucose tolerance as well as reduce or eliminate comorbidities associated with obesity [@bib63], [@bib64], [@bib65]. Thus, there is great interest in reducing overall adiposity while simultaneously enhancing the longevity of beige cells and facilitating their expression in WAT for the prevention of or protection from diet and aged-induced obesity. Our findings in rodents illustrate that a short-term intervention during a specific developmental window with a therapy already in clinical use for human type 2 diabetes can exert a long-term impact on body weight regulation, energy expenditure, and browning of visceral white adipose. This is a critical finding in our ongoing understanding of adipose development and obesity.
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